Figure 3.
Risk of VTE in patients with T2DM receiving GLP-1RA or DPP4i therapy. PY, patient-years.

Risk of VTE in patients with T2DM receiving GLP-1RA or DPP4i therapy. PY, patient-years.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal